US20030089369A1 - Pressurised metered dose inhalers (MDI) - Google Patents

Pressurised metered dose inhalers (MDI) Download PDF

Info

Publication number
US20030089369A1
US20030089369A1 US10/290,225 US29022502A US2003089369A1 US 20030089369 A1 US20030089369 A1 US 20030089369A1 US 29022502 A US29022502 A US 29022502A US 2003089369 A1 US2003089369 A1 US 2003089369A1
Authority
US
United States
Prior art keywords
metered dose
dose inhalers
epoxy
ethanol
hfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/290,225
Inventor
David Lewis
David Ganderton
Brian Meakin
Paolo Ventura
Gaetano Brambilla
Raffaella Garzia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26331622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20030089369(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ITMI982559 external-priority patent/IT1303789B1/en
Priority claimed from IT1999MI001712 external-priority patent/IT1313582B1/en
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Priority to US10/290,225 priority Critical patent/US20030089369A1/en
Publication of US20030089369A1 publication Critical patent/US20030089369A1/en
Priority to US11/060,564 priority patent/US20050142071A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/009Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans

Definitions

  • the invention relates to the use of pressurised metered dose inhalers (MDIs) having part or all of their internal surfaces consisting of stainless steel, anodised aluminium or lined with an inert organic coating.
  • MDIs pressurised metered dose inhalers
  • the invention also relates to compositions to be delivered with said MDIs.
  • Pressurised metered dose inhalers are well known devices for administering pharmaceutical products to the respiratory tract by inhalation.
  • Active materials commonly delivered by inhalation include bronchodilators such as ⁇ 2 agonists and anticholinergics, corticosteroids, anti-leukotrienes, anti-allergics and other materials that may be efficiently administered by inhalation, thus increasing the therapeutic index and reducing side effects of the active material.
  • bronchodilators such as ⁇ 2 agonists and anticholinergics, corticosteroids, anti-leukotrienes, anti-allergics and other materials that may be efficiently administered by inhalation, thus increasing the therapeutic index and reducing side effects of the active material.
  • MDI uses a propellant to expel droplets containing the pharmaceutical product to the respiratory tract as an aerosol.
  • the preferred propellants used in aerosols for pharmaceutical use have been a group of chlorofluorocarbons which are commonly called Freons or CFCs, such as CCl 3 F (Freon 11 or CFC-11), CCl 2 F 2 (Freon 12 or CFC-12), and CClF 2 -CClF 2 (Freon 114 or CFC-114).
  • CFCs chlorofluorocarbons which are commonly called Freons or CFCs, such as CCl 3 F (Freon 11 or CFC-11), CCl 2 F 2 (Freon 12 or CFC-12), and CClF 2 -CClF 2 (Freon 114 or CFC-114).
  • CFC chlorofluorocarbon
  • Hydrofluoroalkanes (HFAs) known also as hydro-fluoro-carbons (HFCs)] contain no chlorine and are considered less destructive to ozone and these are proposed as substitutes for CFCs.
  • HFAs and in particular 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) have been acknowledged to be the best candidates for non-CFC propellants and a number of medicinal aerosol formulations using such HFA propellant systems have been disclosed.
  • HFAs are used as propellant
  • adjuvants including compounds acting as co-solvents, surface active agents including fluorinated and non-fluorinated surfactants, dispersing agents including alkylpolyethoxylates and stabilizers.
  • compositions for aerosol administration via MDIs can be solutions or suspensions.
  • Solution compositions offer several advantages: they are convenient to manufacture being completely dissolved in the propellant vehicle and obviate physical stability problems associated with suspension compositions.
  • WO94/13262 proposes the use of acids as stabilisers preventing the chemical degradation of the active ingredient in aerosol solution formulations comprising HFAs.
  • ipratropium bromide is comprised, for which many composition examples are supplied, in which the active ingredient is in combination with an organic or inorganic acid.
  • WO96/32099, WO96/32150, WO96/32151 and WO96/32345 disclose metered dose inhalers for the administration of different active ingredients in suspension in the propellant, wherein the internal surfaces of the inhaler are partially or completely coated with one or more fluorocarbon polymers optionally in combination with one or more non-fluorocarbon polymers.
  • Said applications do not however address the technical problem of the chemical stability of the active ingredient but they rather concern a different problem, namely that of the adhesion of micronized particles of the suspended active ingredient to the internal surfaces of the inhaler, such as the can walls, valves and sealings. It is also known from Eur. J. Pharm. Biopharm. 1997, 44, 195 that suspensions of drugs in HFA propellant are frequently subjected to absorption of the drug particles on the valves and on the internal walls of the inhaler. The properties of an epoxy phenol resin coating of the aerosol cans have been studied to circumvent this problem.
  • WO95/17195 describes aerosol compositions comprising flunisolide, ethanol and HFA propellants. It is stated in the document that conventional aerosol canisters can be used to contain the composition and that certain containers enhance its chemical and physical stability. It is suggested that the composition can be preferably contained in vials coated with resins such as epoxy resins (e.g. epoxy-phenolic resins and epoxy-urea-formaldehyde resins).
  • resins such as epoxy resins (e.g. epoxy-phenolic resins and epoxy-urea-formaldehyde resins).
  • the preferred material for the aerosol cans is anodised aluminium.
  • epoxy resins in can coatings are produced by the reaction of epichlorohydrin and bisphenol A (DGEBPA). Variations in the molecular weight and in the polymerisation degree result in resins of different properties.
  • Phenoxy resins are other commercially important thermoplastic polymers derived from bisphenols and epichlorohydrin, characterized in that their molecular weights (MWs) are higher, ie, ca 45000, than those of conventional epoxy resins, ie, 8000 and lack terminal epoxide functionality.
  • epoxy-phenol-novolac and epoxy-cresol-novolac resins obtained by glycidylation of the phenol-formaldehyde (novolac) or of the o-cresol-formaldehyde (o-cresol novolac) condensates respectively.
  • the inhalers according to the invention effectively prevent the chemical degradation of the active ingredient.
  • Pressurised metered dose inhalers for dispensing solution of an active ingredient in a hydrofluorocarbon propellant, a co-solvent and optionally a low-volatility component characterized in that part or all of the internal surfaces of said inhalers consist of stainless steel, anodised aluminium or are lined with an inert organic coating.
  • Pressurised metered dose inhalers are known devices, usually consisting of a main body or can, acting as a reservoir for the aerosol formulation, a cap sealing the main body and a metering valve fitted in the cap.
  • MDIs are usually made of a conventional material such as aluminium, tin plate, glass, plastic and the like.
  • part or all of the internal surfaces of the inhalers consists of stainless steel, anodised aluminium or is lined with an inert organic coating.
  • One of the preferred coating consists of epoxy-phenol resin. Any kind of stainless steel may be used. Suitable epoxy-phenol resins are commercially available.
  • Active ingredients which may be used in the aerosol compositions to be dispensed with the inhalers of the invention are any ingredient which can be administered by inhalation and which meets problems of chemical stability in solution in HFA propellants giving rise to a decomposition when stored in conventional materials cans and in particular in aluminium cans.
  • the hydrofluorocarbon propellant is preferably selected from the group of HFA 134a, HFA 227 and mixtures thereof.
  • the co-solvent is usually an alcohol, preferably ethanol.
  • the low volatility component when present, is selected from the group of glycols, particularly propylene glycol, polyethylene glycol and glycerol, alkanols such as decanol (decyl alcohol), sugar alcohols including sorbitol, mannitol, lactitol and maltitol, glycofural (tetrahydro-furfurylalcohol) and dipropylene glycol, vegetable oils, organic acids for example saturated carboxylic acids including lauric acid, myristic acid and stearic acid; unsaturated carboxylic acids including sorbic acid, and especially oleic acid; saccharine, ascorbic acid, cyclamic acid, amino acids, or aspartame, esters for example ascorbyl palmitate, isopropyl myristate and tocopherol esters; alkanes for example dodecane and octadecane; terpenes for
  • the aerosols compositions to be delivered with the pressurised MDIs of the invention may contain from 0.2 to 2% by weight of said low volatility component.
  • Propylene glycol, polyethylene glycol, isopropyl myristate and glycerol are particularly preferred low-volatility components.
  • the function of the low volatility component is to modulate the MMAD of the aerosol particles. Being used at very low concentrations, it does not substantially affect the chemical stability of the compositions.
  • active ingredients include: anticholinergics such as ipratropium bromide, oxitropium bromide, tiotropium bromide; acetal corticosteroids such as budesonide, ciclesonide, rofleponide; ginal corticosteroids such as flunisolide, triamcinolone acetonide; other corticosteroids such as fluticasone propionate, mometasone furoate; short or long acting beta-adrenergic agonists such as salbutamol, formoterol, salmeterol, TA 2005 and their combinations.
  • anticholinergics such as ipratropium bromide, oxitropium bromide, tiotropium bromide
  • acetal corticosteroids such as budesonide, ciclesonide, rofleponide
  • chetal corticosteroids such as flunisolide, triamcinolone acetonide
  • WO 94/13262 teaches that problems of chemical stability of medicaments and in particular of ipratropium bromide in aerosol solution compositions can be solved adding an acid, either an inorganic acid or an organic acid, to the HFA propellant/cosolvent system.
  • compositions containing ipratropium bromide in HFA 134a/ethanol systems further containing an inorganic acid such as hydrochloric, nitric, phosphoric or sulfuric acid or an organic acid such as ascorbic or citric acid are provided.
  • compositions comprising ipratropium bromide, a propellant containing a hydrofluoroalkane, a cosolvent and further comprising a low volatility component:
  • ipratropium bromide with or without acids is stable in stainless steel, anodised aluminium or in some types of epoxy phenol resin lined cans;
  • Another preferred active ingredient for the preparation of solution compositions in a HFA/cosolvent system to be dispensed by MDIs according to the present invention is budesonide.
  • Previously HFA/budesonide compositions have been described, in which budesonide is present in suspension in the propellant system and the composition further comprises additional ingredients such as particular kinds of surfactants (EP 504112, WO 93/05765, WO 93/18746, WO 94/21229).
  • compositions containing a mixture of HFA propellants to match the density of the propellant mixture to be substantially identical to the density of budesonide, up to 3% of an adjuvant such as ethanol and small amounts of surfactant.
  • budesonide is chemically and physically stable.
  • aerosol compositions of the invention distributed in inhalers having the internal surfaces consisting of stainless steel, anodised aluminium or coated with an inert material and preferably with epoxy-phenol resin are stable for long periods and do not undergo chemical degradation.
  • the low volatility component may also act as a co-solvent, thus increasing the solubility of the drug in the formulation and increasing the physical stability and/or allowing the possibility to decrease the quantity of co-solvent required.
  • a composition containing 4.8 mg of ipratropium bromide (20 ⁇ g/dose), 13% (w/w) ethanol, 1.0% (w/w) glycerol and HFA 134a to 12 ml/can was distributed in stainless steel, anodised aluminium, standard aluminium cans or in cans having different internal coatings and were stored at various conditions.
  • the percent drug remaining in the composition shows that stainless steel and anodised aluminium cans as well as epoxy-phenol resins (1), (2) and (4) coated cans are effective in preventing the chemical degradation of ipratropium bromide, differently from glass cans or other tested coatings.
  • Citric, ascorbic and hydrochloric acids were added to the formulations in the amounts reported in Table 3.
  • compositions were tested after 1, 2 and 5 months storage at 40° C. in epoxy-phenol resin (4) coated cans.
  • compositions containing 12 mg of budesonide (50 ⁇ g/dose), 13% or 15% (w/w) ethanol, 1.3% (w/w) glycerol in HFA 134a to 12 ml/can were distributed in stainless steel, anodised aluminium, standard aluminium, glass cans or in cans having different internal coatings and were stored at various conditions.
  • compositions containing 7.2, 12, 16.8 mg of dexbudesonide (corresponding to 30, 50 and 70 ⁇ g/dose respectively), ethanol, 0.9 (w/w) PEG 400 or isopropyl myristate (IPM) in HFA 227 to 12 ml can was distributed in aluminium anodised cans and was stored 70 days at 50° C. The results are reported in Table 6.
  • the FPD gives a direct measure of the mass of particles within the specified size range and is closely related to the efficacy of the product.
  • a composition containing 60 mg of flunisolide (250 ⁇ g/dose), 15% (w/w) ethanol, 1% (w/w) glycerol in HFA 134a to 12 ml/can was distributed in anodised aluminium, glass cans or in cans having different internal coatings and were stored for 41 days at 50° C.
  • the percent drug remaining in the composition shows the favourable effect of anodised aluminium and inert coating with epoxy-phenol resins on the chemical stability of the active ingredient in respect to glass cans.
  • micronized budesonide in ethanol is 31.756 mg/g.
  • Epoxy phenol resin 99 89 88.5 93.5 (1) (90) (89.5) (94.5) Epoxy phenol resin 97.5 90 88.5 89 (2) (92) (90.5) (91) Epoxy phenol resin 98.5 56.5 46 52.5 (3) (57.5) (47) (53.5) Anodised aluminum 94 89 87 90.5 (95) (92.5) (96.5) Glass type III* — 48.5 41.5 47 ( ⁇ ) ( ⁇ ) ( ⁇ )

Abstract

The invention relates to the use of pressurised metered dose inhalers (MDIs) having part or all of their internal surfaces consisting of stainless steel, anodised aluminium or lined with an inert organic coating; and to compositions to be delivered with said MDIs.

Description

  • The invention relates to the use of pressurised metered dose inhalers (MDIs) having part or all of their internal surfaces consisting of stainless steel, anodised aluminium or lined with an inert organic coating. The invention also relates to compositions to be delivered with said MDIs. [0001]
  • Pressurised metered dose inhalers are well known devices for administering pharmaceutical products to the respiratory tract by inhalation. [0002]
  • Active materials commonly delivered by inhalation include bronchodilators such as β2 agonists and anticholinergics, corticosteroids, anti-leukotrienes, anti-allergics and other materials that may be efficiently administered by inhalation, thus increasing the therapeutic index and reducing side effects of the active material. [0003]
  • MDI uses a propellant to expel droplets containing the pharmaceutical product to the respiratory tract as an aerosol. [0004]
  • For many years the preferred propellants used in aerosols for pharmaceutical use have been a group of chlorofluorocarbons which are commonly called Freons or CFCs, such as CCl[0005] 3F (Freon 11 or CFC-11), CCl2F2 (Freon 12 or CFC-12), and CClF2-CClF2 (Freon 114 or CFC-114).
  • Recently, the chlorofluorocarbon (CFC) propellants such as Freon 11 and Freon 12 have been implicated in the destruction of the ozone layer and their production is being phased out. [0006]
  • Hydrofluoroalkanes [(HFAs) known also as hydro-fluoro-carbons (HFCs)] contain no chlorine and are considered less destructive to ozone and these are proposed as substitutes for CFCs. [0007]
  • HFAs and in particular 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) have been acknowledged to be the best candidates for non-CFC propellants and a number of medicinal aerosol formulations using such HFA propellant systems have been disclosed. [0008]
  • Many of these applications, in which HFAs are used as propellant, propose the addition of one or more of adjuvants including compounds acting as co-solvents, surface active agents including fluorinated and non-fluorinated surfactants, dispersing agents including alkylpolyethoxylates and stabilizers. [0009]
  • In the international application No. PCT/EP98/03533 filed on Oct. 06, 1998 the applicant described solution compositions for use in an aerosol inhaler, comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler. [0010]
  • Compositions for aerosol administration via MDIs can be solutions or suspensions. Solution compositions offer several advantages: they are convenient to manufacture being completely dissolved in the propellant vehicle and obviate physical stability problems associated with suspension compositions. [0011]
  • The widespread use of these formulations is limited by their chemical instability, causing the formation of degradation products. [0012]
  • WO94/13262 proposes the use of acids as stabilisers preventing the chemical degradation of the active ingredient in aerosol solution formulations comprising HFAs. Among the selected medicaments ipratropium bromide is comprised, for which many composition examples are supplied, in which the active ingredient is in combination with an organic or inorganic acid. [0013]
  • WO96/32099, WO96/32150, WO96/32151 and WO96/32345 disclose metered dose inhalers for the administration of different active ingredients in suspension in the propellant, wherein the internal surfaces of the inhaler are partially or completely coated with one or more fluorocarbon polymers optionally in combination with one or more non-fluorocarbon polymers. [0014]
  • Said applications do not however address the technical problem of the chemical stability of the active ingredient but they rather concern a different problem, namely that of the adhesion of micronized particles of the suspended active ingredient to the internal surfaces of the inhaler, such as the can walls, valves and sealings. It is also known from Eur. J. Pharm. Biopharm. 1997, 44, 195 that suspensions of drugs in HFA propellant are frequently subjected to absorption of the drug particles on the valves and on the internal walls of the inhaler. The properties of an epoxy phenol resin coating of the aerosol cans have been studied to circumvent this problem. [0015]
  • WO95/17195 describes aerosol compositions comprising flunisolide, ethanol and HFA propellants. It is stated in the document that conventional aerosol canisters can be used to contain the composition and that certain containers enhance its chemical and physical stability. It is suggested that the composition can be preferably contained in vials coated with resins such as epoxy resins (e.g. epoxy-phenolic resins and epoxy-urea-formaldehyde resins). [0016]
  • Actually the results reported in Tables 5, 6 and 8 respectively on pages 16 and 19 of the cited application demonstrate that flunisolide decomposes only in plastic cans (Table 8), and that the percent drug recovery in compositions stored in aluminium, glass or epoxy-phenol formaldehyde resin coated vials is practically the same (Table 8). In other words there is no difference between aluminium, glass type III or epoxy/phenol-formaldehyde resin coated aluminium vials coated by Cebal. No data are reported for other types of epoxy resins. [0017]
  • It has now been found that the chemical stability problems of active ingredients in solution in HFA propellants can be eliminated by storing and delivering said composition employing metered-dose inhalers having part or all of their internal metallic surfaces consisting of stainless steel, anodised aluminium or lined with an inert organic coating. [0018]
  • The preferred material for the aerosol cans is anodised aluminium. [0019]
  • In the case of epoxy-phenol resin coating the choice of the suitable coating will be opportunely made on the basis of the characteristics of the active ingredient. [0020]
  • The most widely used epoxy resins in can coatings are produced by the reaction of epichlorohydrin and bisphenol A (DGEBPA). Variations in the molecular weight and in the polymerisation degree result in resins of different properties. [0021]
  • Phenoxy resins are other commercially important thermoplastic polymers derived from bisphenols and epichlorohydrin, characterized in that their molecular weights (MWs) are higher, ie, ca 45000, than those of conventional epoxy resins, ie, 8000 and lack terminal epoxide functionality. [0022]
  • Other multifunctional resins are epoxy-phenol-novolac and epoxy-cresol-novolac resins obtained by glycidylation of the phenol-formaldehyde (novolac) or of the o-cresol-formaldehyde (o-cresol novolac) condensates respectively. [0023]
  • The inhalers according to the invention effectively prevent the chemical degradation of the active ingredient. [0024]
  • Surprisingly and contrary to what reported in the prior art with regard to flunisolide, we found a considerable degradation of the tested active ingredients when their formulations were stored in glass containers type III. [0025]
  • SUMMARY OF THE INVENTION
  • Pressurised metered dose inhalers for dispensing solution of an active ingredient in a hydrofluorocarbon propellant, a co-solvent and optionally a low-volatility component characterized in that part or all of the internal surfaces of said inhalers consist of stainless steel, anodised aluminium or are lined with an inert organic coating. [0026]
  • DETAILED DESCRIPTION OF THE INVENTION
  • Pressurised metered dose inhalers are known devices, usually consisting of a main body or can, acting as a reservoir for the aerosol formulation, a cap sealing the main body and a metering valve fitted in the cap. [0027]
  • MDIs are usually made of a conventional material such as aluminium, tin plate, glass, plastic and the like. [0028]
  • According to the invention, part or all of the internal surfaces of the inhalers consists of stainless steel, anodised aluminium or is lined with an inert organic coating. One of the preferred coating consists of epoxy-phenol resin. Any kind of stainless steel may be used. Suitable epoxy-phenol resins are commercially available. [0029]
  • Active ingredients which may be used in the aerosol compositions to be dispensed with the inhalers of the invention are any ingredient which can be administered by inhalation and which meets problems of chemical stability in solution in HFA propellants giving rise to a decomposition when stored in conventional materials cans and in particular in aluminium cans. [0030]
  • In the compositions to be delivered with the MDIs of the invention the hydrofluorocarbon propellant is preferably selected from the group of HFA 134a, HFA 227 and mixtures thereof. [0031]
  • The co-solvent is usually an alcohol, preferably ethanol. The low volatility component, when present, is selected from the group of glycols, particularly propylene glycol, polyethylene glycol and glycerol, alkanols such as decanol (decyl alcohol), sugar alcohols including sorbitol, mannitol, lactitol and maltitol, glycofural (tetrahydro-furfurylalcohol) and dipropylene glycol, vegetable oils, organic acids for example saturated carboxylic acids including lauric acid, myristic acid and stearic acid; unsaturated carboxylic acids including sorbic acid, and especially oleic acid; saccharine, ascorbic acid, cyclamic acid, amino acids, or aspartame, esters for example ascorbyl palmitate, isopropyl myristate and tocopherol esters; alkanes for example dodecane and octadecane; terpenes for example menthol, eucalyptol, limonene; sugars for example lactose, glucose, sucrose; polysaccharides for example ethyl cellulose, dextran; antioxidants for example butylated hydroxytoluene, butylated hydroxyanisole; polymeric materials for example polyvinyl alcohol, polyvinyl acetate, polyvinyl pyrrolidone; amines for example ethanolamine, diethanolamine, triethanolamine; steroids for example cholesterol, cholesterol esters. The low-volatility component has a vapour pressure at 25° C. lower than 0.1 kPa, preferably lower than 0.05 kPa. [0032]
  • The aerosols compositions to be delivered with the pressurised MDIs of the invention may contain from 0.2 to 2% by weight of said low volatility component. [0033]
  • Propylene glycol, polyethylene glycol, isopropyl myristate and glycerol are particularly preferred low-volatility components. [0034]
  • The function of the low volatility component is to modulate the MMAD of the aerosol particles. Being used at very low concentrations, it does not substantially affect the chemical stability of the compositions. [0035]
  • Examples of active ingredients include: anticholinergics such as ipratropium bromide, oxitropium bromide, tiotropium bromide; acetal corticosteroids such as budesonide, ciclesonide, rofleponide; chetal corticosteroids such as flunisolide, triamcinolone acetonide; other corticosteroids such as fluticasone propionate, mometasone furoate; short or long acting beta-adrenergic agonists such as salbutamol, formoterol, salmeterol, TA 2005 and their combinations. The active ingredients when possible may be present in racemic mixtures or in form of a single enantiomer or epimer. [0036]
  • As said before, WO 94/13262 teaches that problems of chemical stability of medicaments and in particular of ipratropium bromide in aerosol solution compositions can be solved adding an acid, either an inorganic acid or an organic acid, to the HFA propellant/cosolvent system. [0037]
  • Examples of compositions containing ipratropium bromide in HFA 134a/ethanol systems further containing an inorganic acid such as hydrochloric, nitric, phosphoric or sulfuric acid or an organic acid such as ascorbic or citric acid are provided. [0038]
  • We found that in solution compositions comprising ipratropium bromide, a propellant containing a hydrofluoroalkane, a cosolvent and further comprising a low volatility component: [0039]
  • a) different decomposition rates occur with different acids: for example we found that ipratropium bromide (20 μg/dose) in a composition of 13% (w/w) ethanol, 1.0% (w/w) glycerol, 20 μl/can of 1N hydrochloric acid and HFA 134a to 12 ml/can rapidly decomposes and after 3 months storage at 40° C. gives 85.0% average of drug remaining; [0040]
  • b) ipratropium bromide with or without acids is stable in stainless steel, anodised aluminium or in some types of epoxy phenol resin lined cans; [0041]
  • c) surprisingly certain kinds of materials, such as glass, coatings proposed in the prior-art to overcome the physical absorption phenomenon of the active ingredient, such as perfluoroalkoxyalkanes and fluorinated-ethylene-propylene polyether sulfone resins, or certain kinds of epoxy phenol coatings turned out to be completely unsatisfactory and ineffective in preventing its chemical degradation. [0042]
  • Another preferred active ingredient for the preparation of solution compositions in a HFA/cosolvent system to be dispensed by MDIs according to the present invention is budesonide. [0043]
  • Previously HFA/budesonide compositions have been described, in which budesonide is present in suspension in the propellant system and the composition further comprises additional ingredients such as particular kinds of surfactants (EP 504112, WO 93/05765, WO 93/18746, WO 94/21229). [0044]
  • In WO 98/13031 it is reported that suspension formulations of budesonide have a propensity to rapidly form coarse flocs upon dispersion and redispersion which may deleteriously affect dosage reproducibility. There is also a tendency for budesonide to deposit from suspension onto the walls of the container. [0045]
  • To achieve stable suspensions of particulate budesonide it is employed in the prior art a composition containing a mixture of HFA propellants to match the density of the propellant mixture to be substantially identical to the density of budesonide, up to 3% of an adjuvant such as ethanol and small amounts of surfactant. [0046]
  • It is stated in the document that the levels of the adjuvants are low to avoid significant solubilization of drug, leading to a problem of chemical degradation and particle size increase on storage. [0047]
  • In the solution compositions of the present invention budesonide is chemically and physically stable. [0048]
  • The aerosol compositions of the invention distributed in inhalers having the internal surfaces consisting of stainless steel, anodised aluminium or coated with an inert material and preferably with epoxy-phenol resin are stable for long periods and do not undergo chemical degradation. [0049]
  • Also in this case a considerable degradation of the active ingredient was noticed when glass containers were used. [0050]
  • Analogously flunisolide and dexbudesonide (the 22R-epimer of budesonide) solutions in HFA propellant containing ethanol and a low-volatility component are stable when stored in inhalers having the internal surfaces consisting of anodised aluminium or coated with epoxy-phenol resin. Evident degradation of flunisolide was noticed when glass containers were used. [0051]
  • It has been also found that the low volatility component may also act as a co-solvent, thus increasing the solubility of the drug in the formulation and increasing the physical stability and/or allowing the possibility to decrease the quantity of co-solvent required. [0052]
  • The following examples further illustrate the invention. In the examples and tables the different types of epoxy phenol resins are indicated with numbers in brackets corresponding to: [0053]
  • (1) Epoxy-phenol lacquered aluminium vials coated by Cebal [0054]
  • (2) Epoxy-phenol lacquered aluminium vials coated by Presspart [0055]
  • (3) Epoxy-phenol lacquered aluminium vials coated by Nussbaum & Guhl [0056]
  • (4) Epoxy-phenol lacquered aluminium vials coated by Presspart, other than (2)[0057]
  • EXAMPLE 1
  • A composition containing 4.8 mg of ipratropium bromide (20 μg/dose), 13% (w/w) ethanol, 1.0% (w/w) glycerol and HFA 134a to 12 ml/can was distributed in stainless steel, anodised aluminium, standard aluminium cans or in cans having different internal coatings and were stored at various conditions. [0058]
  • The results are reported in Table 1 and Table 2. [0059]
  • The percent drug remaining in the composition, measured by HPLC, shows that stainless steel and anodised aluminium cans as well as epoxy-phenol resins (1), (2) and (4) coated cans are effective in preventing the chemical degradation of ipratropium bromide, differently from glass cans or other tested coatings. [0060]
  • EXAMPLE 2
  • The effect of different acids on the chemical stability of the composition of Example 1 was studied. [0061]
  • Citric, ascorbic and hydrochloric acids were added to the formulations in the amounts reported in Table 3. [0062]
  • The stability of the compositions was tested after 1, 2 and 5 months storage at 40° C. in epoxy-phenol resin (4) coated cans. [0063]
  • EXAMPLE 3
  • Compositions containing 12 mg of budesonide (50 μg/dose), 13% or 15% (w/w) ethanol, 1.3% (w/w) glycerol in HFA 134a to 12 ml/can were distributed in stainless steel, anodised aluminium, standard aluminium, glass cans or in cans having different internal coatings and were stored at various conditions. [0064]
  • The results are reported in Table 4 and 5. [0065]
  • The percent drug remaining in the compositions, measured by HPLC, shows the favourable effect of stainless steel, anodised aluminium and inert coating on the chemical stability of the active ingredient in respect to standard aluminium or glass cans. The best results have been obtained with stainless steel, anodised aluminium cans and with epoxy-phenol or perfluoroalkoxyalkane coatings. [0066]
  • EXAMPLE 4 [0067]
  • A composition containing 48 mg of dexbudesonide (200 μg/dose), 15% (w/w) ethanol, 1.3% (w/w) glycerol in HFA 134a to 12 ml can was distributed in epoxy-phenol lacquered aluminium cans and was stored at 40° C. [0068]
  • The percent drug remaining in the composition after 8 months, measured by HPLC, was 95.4% (average value referred to two tests). [0069]
  • The control of the epimeric distribution showed that there is no transfer from the 22R to the 22S epimer. [0070]
  • EXAMPLE 5
  • Compositions containing 7.2, 12, 16.8 mg of dexbudesonide (corresponding to 30, 50 and 70 μg/dose respectively), ethanol, 0.9 (w/w) PEG 400 or isopropyl myristate (IPM) in HFA 227 to 12 ml can was distributed in aluminium anodised cans and was stored 70 days at 50° C. The results are reported in Table 6. [0071]
  • The percent drug remaining in the composition measured by HPLC shows the favourable effect of anodised aluminium cans on the chemical stability of the active ingredient. The control of the epimeric distribution showed that there is no transfer from the 22R to the 22S epimer. [0072]
  • ENAMPLE 6
  • The fine particle dose (FPD: weight of particles having an aerodynamic diameter lower than 4.7 μm) of dexbudesonide solution compositions in HFA 134a or HFA 227, prepared following the examples 4 and 5, was determined. [0073]
  • The experiments were performed using the Andersen Cascade Impactor and the data obtained are average values from 10 shots. [0074]
  • The results, reported in Table 7 and 8 show that dexbudesonide formulations of the invention are characterized by a very low dose and a very high fine particle dose. [0075]
  • The FPD gives a direct measure of the mass of particles within the specified size range and is closely related to the efficacy of the product. [0076]
  • EXAMPLE 7
  • A composition containing 60 mg of flunisolide (250 μg/dose), 15% (w/w) ethanol, 1% (w/w) glycerol in HFA 134a to 12 ml/can was distributed in anodised aluminium, glass cans or in cans having different internal coatings and were stored for 41 days at 50° C. [0077]
  • The results are reported in Table 9. [0078]
  • The percent drug remaining in the composition, measured by HPLC, shows the favourable effect of anodised aluminium and inert coating with epoxy-phenol resins on the chemical stability of the active ingredient in respect to glass cans. [0079]
  • Example 8
  • The solubility of ipratropium bromide and micronized budesonide in ethanol, glycerol and their mixtures has been investigated. [0080]
  • The tests were carried out at room temperature. [0081]
  • a) Solubility in Ethanol. [0082]
  • About 8.5 g of absolute ethanol were weighed into a flask. The active ingredient (Ipratropium Bromide or Budesonide) was added in small amounts, under magnetic stirrer, until no further dissolution occurred (i.e.: a saturated solution was obtained). The flask was stirred for about 40 minutes, and left to settle overnight prior to analysis, to let the system equilibrate. The flask was kept sealed, to avoid evaporation. [0083]
  • The solution obtained was then filtered and tested for the amount of active ingredient, according to the conventional analytical procedure. [0084]
  • b) Solubility in Ethanol/Glycerol Mixtures. [0085]
  • The required amounts of ethanol and glycerol were weighted into a flask, and mixed by a magnetic stirrer until a homogeneous phase was obtained. [0086]
  • The solubility of ipratropium bromide in ethanol is 42.48 mg/g. [0087]
  • The solubility data of ipratropium bromide in ethanol/glycerol mixtures are listed in Table 10. [0088]
  • The solubility of micronized budesonide in ethanol is 31.756 mg/g. [0089]
  • Solubility data of micronized budesonide in ethanol/glycerol mixtures are listed in Table 11. [0090]
  • The data show that both the tested active ingredients are rather soluble in ethanol, and that their solubility increases even when small percentages of glycerol are added. [0091]
  • The increase in solubility is maintained also in presence of HFA propellants. [0092]
    TABLE 1
    Percent ipratropium bromide (IPBr) recovered
    after storing the composition of Example 1 for
    8 months at 40° C. in cans of different types
    CAN TYPE % RESIDUAL IPBr
    Epoxy-phenol resin (4) 96
    Perfluoroalkoxyalkane 57
    Fluorinated-ethylene-propylene/ 78
    polyether sulphone (Xylan 8840(R))
    Stainless steel 96
    Standard aluminium 46
  • [0093]
    TABLE 2
    Percent ipratropium bromide (IPBr)
    recovered after storing the composition of
    Example 1 for 30 and 60 days at 50° C., or
    for 96 days at 40° C. in cans of different
    types (average values referred to two tests).
    % RESIDUAL IPBr
    (% RESIDUAL IPBr RELATIVE TO t = 0)
    t = 30 days t = 60 days t = 96 days
    CAN TYPE t = 0 at 50° C. at 50° C. at 40° C.
    Epoxy phenol resin 99 89 88.5 93.5
    (1) (90) (89.5) (94.5)
    Epoxy phenol resin 97.5 90 88.5 89
    (2) (92) (90.5) (91)
    Epoxy phenol resin 98.5 56.5 46 52.5
    (3) (57.5) (47) (53.5)
    Anodised aluminum 94 89 87 90.5
    (95) (92.5) (96.5)
    Glass type III* 48.5 41.5 47
    (−) (−) (−)
  • [0094]
    TABLE 3
    Percent ipratropium bromide (IPBr)
    recovered after storing the compositions
    of Example 1, with different acids added,
    in epoxy-phenol (4) coated cans (average
    values referred to two tests)
    % RESIDUAL IPBr
    (% RESIDUAL IPBr RELATIVE TO t = 0)
    t = 1 month t = 2 months t = 5 months
    Acid t = 0 at 40° C. at 40° C. at 40° C.
    Citric
    (0.6% w/w) 98 98 99 94
    (100)  (101)  (96)
    (0.3% w/w) 99 99 100  97
    (100)  (101)  (98)
    (0.07% w/w) 99 98 99 96
    (99) (100)  (97)
    Ascorbic 119 113  112  110 
    (95) (94) (92)
    Hydrochloric
    (4 μl-1N) 101 100  104  96
    (99) (102)  (95)
    (10 μl-1N) 101 98 98 97
    (97) (97) (96)
    (20 μl-1N) 100 95 98 97
    (95) (98) (97)
    None 97 97 98 95
    (100)  (101)  (98)
  • [0095]
    TABLE 4
    Percent budesonide recovered after storing
    the composition of Example 3 (13% ethanol) for
    7 months at 40° C. in cans of different types
    CAN TYPE % RESIDUAL BUDESONIDE
    Epoxy-phenol resin (4) 100
    Fluorinated-ethylene-propylene/ 93.5
    polyether sulphone (Xylan 8840(R))
    Stainless steel 97
    Aluminium 68
    Perfluoroalkoxyalkane 100
  • [0096]
    TABLE 5
    Percent budesonide recovered after storing
    the composition of Example 3 (15% ethanol)
    for 33 and 73 days at 50° C. in cans of
    different types (average values referred to
    two tests).
    % RESIDUAL BUDESONIDE
    (% RESIDUAL BUDESONIDE
    RELATIVE TO t = 0)
    CAN TYPE t = 0 T = 33 days t = 73 days
    Epoxy phenol 99.3 97.0 95.4
    resin (1) (97.7) (96.1)
    Epoxy phenol 99.5 96.6 95.6
    resin (2) (97.0) (96.1)
    Epoxy phenol 99.3 96.6 95.9
    resin (3) (97.2) (96.5)
    Anodised 99.9 99.2 97.7
    aluminium (99.3) (97.8)
    Glass type III* 86.15 80.4
    (−) (−)
  • [0097]
    TABLE 6
    Percent dexbudesonide recovered after
    storing the compositions of Example 5 for
    70 days at 50° C. in anodised aluminium cans
    (average values referred to two tests).
    % Residual dexbudesonide
    Metered (% residual dexbudesonide
    dose Ethanol Low vol. comp. relative to t = 0)
    (μg) % (w/w) 0.9% (w/w) t = 0 days t = 70 days
    30 5 PEG 400 95.8 95.8
    (100)
    IPM 98.1 96.8
    (98.7)
    50 8 PEG 400 99.0 98.0
    (98.9)
    IPM 98.0 99.4
    (101)
    70 7 PEG 400 95.7 93.75
    (98.0)
    IPM 100.4 96.3
    (96.0)
  • [0098]
    TABLE 7
    Fine particle dose (FPD) values of
    dexbudesonide solution formulation in HFA
    134a containing:
    dexbudesonide 14.4 mg/can (60 μg/shot)
    ethanol 8% (w/w)
    low volatility compound 0.9% (w/w)
    HFA 134a to 12 ml can (valve chamber volume = 63 μl)
    MMAD = 2.0 μm
    Low
    volatility FPD FPF Metered dose Delivered dose
    Compound (μg) (%) (μg) (μg)
    IPM 39.9 73.6 57.9 54.2
    IPM 39.4 77.4 53.2 50.9
  • [0099]
    TABLE 8
    Fine particle dose (FPD) values of
    dexbudesonide solution formulation in HFA
    227 containing:
    dexbudesonide 15.12 mg/can (63 μg/shot)
    ethanol 7% (w/w)
    low volatility compound 0.9% (w/w)
    HFA 227 to 12 ml can (valve chamber volume = 63 μl)
    MMAD = 2.0 μm
    Low
    volatility FPD FPF Metered dose Delivered dose
    Compound (μg) (%) (μg) (μg)
    IPM 45.0 75.5 63.9 59.7
    PEG 400 48.5 78.9 65.5 61.5
  • [0100]
    TABLE 9
    Percent flunisolide recovered after storing
    the composition of Example 7 for 41 days at
    50° C. in cans of different types (average
    values referred to two tests)
    % RESIDUAL FLUNISOLIDE
    (% RESIDUAL FLUNISOLIDE
    RELATIVE TO t = 0)
    CAN TYPE t = 0 t = 41 days t = 93 days
    Epoxy phenol 98.4 99.2 101.4
    resin (1) (101) (103)
    Epoxy phenol 101.9 99.7 101.9
    resin (2) (97.8) (100)
    Epoxy phenol 101.7 99.2 101.2
    resin (3) (97.5) (99.6)
    Anodised 101.6 100.4 100.7
    aluminium (98.8) (99.1)
    Glass type III* 97.5
    (−)
  • [0101]
    TABLE 10
    Solubility of Ipratropium Bromide in
    ethanol/glycerol mixtures
    Ipratropium
    Bromide
    Ethanol (%) Glycerol (%) solubility (mg/g)
    100 0 42.8
    92.6 7.4 74.0
    91.9 8.1 74.7
    91.3 8.7 90.5
    88.4 11.6 98.0
    82.6 17.4 115.6
    71.4 28.6 196.7
    60 40 271.6
    40 60 307.2
    21.1 78.9 265.7
    0 100 73.4
  • [0102]
    TABLE 11
    Solubility of micronized Budesonide in
    ethanol/glycerol mixtures
    Budesonide
    solubility
    Ethanol (%) Glycerol (%) (mg/g)
    100 0 31.756
    92.5 7.5 36.264
    91.9 8.1 36.277
    91.3 8.7 37.328
    87.7 12.3 38.364
    83.3 16.7 37.209
    71.4 28.6 35.768
    60 40 28.962
    39.9 60.1 14.840
    21.1 78.9 3.990
    0 100 0.214

Claims (11)

1. Pressurised metered dose inhalers containing a solution of an active ingredient in a hydrofluorocarbon propellant, a co-solvent and optionally a low-volatility component characterised in that part or all of the internal surfaces of said inhalers consist of stainless steel, anodised aluminium or are lined with an inert organic coating.
2. Pressurized metered dose inhalers according to claim 1, wherein the active ingredients are selected from β2 agonists, steroids or anti-cholinergic agents and their combinations.
3. Pressurized metered dose inhalers according to claim 2, wherein the active ingredient is ipratropium bromide, oxitropium bromide, tiotropium bromide, flunisolide, triamcinolone acetonide, fluticasone propionate, mometasone furoate, budesonide, ciclesonide, rofleponide and epimers thereof.
4. Pressurized metered dose inhalers according to any of claims from 1 to 3, containing a low-volatility component selected from glycerol, polyethylene glycol and isopropyl myristate.
5. Pressurized metered dose inhalers according to any of claims from 1 to 4, wherein the co-solvent is ethanol.
6. Pressurized metered dose inhalers according to any of claims from 1 to 5, wherein the propellant is selected from HFA 227, HFA 134a and their mixtures.
7. Pressurised metered dose inhalers according to any of claims 1 to 6 wherein the inert organic coating is perfluoroalkoxyalkane, epoxy-phenol resin or fluorinated-ethylene-propylene polyether sulfone.
8. Pressurised metered dose inhalers according to any of claims 1 to 7 wherein part or all of the internal surfaces are coated with an epoxy phenol resin.
9. Pressurised metered dose inhalers according to any of claims 1 to 6 wherein part or all of the internal surfaces consist of anodised aluminium.
10. Stabilized aerosol solution formulation consisting of an active ingredient in a hydrofluorocarbon propellant, a co-solvent and optionally a low-volatility component for use in a pressurised metered dose inhaler as claimed in any of claims 1 to 9.
11. Aerosol solution formulation of dexbudesonide in a hydrofluorocarbon propellant and ethanol as a co-solvent, further comprising a low volatility compound selected from glycerol, isopropylmyristate and polyethylene glicol.
US10/290,225 1998-11-25 2002-11-08 Pressurised metered dose inhalers (MDI) Abandoned US20030089369A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/290,225 US20030089369A1 (en) 1998-11-25 2002-11-08 Pressurised metered dose inhalers (MDI)
US11/060,564 US20050142071A1 (en) 1998-11-25 2005-02-18 Pressurised metered dose inhalers (MDI)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
ITMI98A002559 1998-11-25
ITMI982559 IT1303789B1 (en) 1998-11-25 1998-11-25 New pressured metered dose inhalers (MDI) in which all the internal surfaces of the inhalers are stainless steel, anodised aluminum or are lined with an inert organic coating are new
IT1999MI001712 IT1313582B1 (en) 1999-07-30 1999-07-30 New pressured metered dose inhalers (MDI) in which all the internal surfaces of the inhalers are stainless steel, anodised aluminum or are lined with an inert organic coating are new
ITMI99A001712 1999-07-30
US83188801A 2001-07-19 2001-07-19
US10/290,225 US20030089369A1 (en) 1998-11-25 2002-11-08 Pressurised metered dose inhalers (MDI)

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US09/831,888 Continuation US7347199B1 (en) 1998-11-25 1999-11-23 Pressurised metered dose inhalers (MDI)
PCT/EP1999/009002 Continuation WO2000030608A1 (en) 1998-11-25 1999-11-23 Pressurised metered dose inhalers (mdi)
US83188801A Continuation 1998-11-25 2001-07-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/060,564 Continuation US20050142071A1 (en) 1998-11-25 2005-02-18 Pressurised metered dose inhalers (MDI)

Publications (1)

Publication Number Publication Date
US20030089369A1 true US20030089369A1 (en) 2003-05-15

Family

ID=26331622

Family Applications (8)

Application Number Title Priority Date Filing Date
US09/831,888 Expired - Fee Related US7347199B1 (en) 1998-11-25 1999-11-23 Pressurised metered dose inhalers (MDI)
US10/244,519 Expired - Fee Related US7223381B2 (en) 1998-11-25 2002-09-17 Pressurised metered dose inhalers (MDI)
US10/290,225 Abandoned US20030089369A1 (en) 1998-11-25 2002-11-08 Pressurised metered dose inhalers (MDI)
US10/612,072 Expired - Fee Related US7740463B2 (en) 1998-11-25 2003-07-03 Pressurised metered dose inhalers (MDI)
US11/060,564 Abandoned US20050142071A1 (en) 1998-11-25 2005-02-18 Pressurised metered dose inhalers (MDI)
US12/023,315 Expired - Fee Related US8142763B2 (en) 1998-11-25 2008-01-31 Pressurized metered dose inhalers (MDI) containing a solution comprising ipratropium bromide, HFA propellant, and co-solvent and comprising a container with a specific internal surface composition and/or lining
US12/132,852 Abandoned US20080247965A1 (en) 1998-11-25 2008-06-04 Pressurised metered dose inhalers (mdi)
US13/004,204 Abandoned US20110100361A1 (en) 1998-11-25 2011-01-11 Pressurised metered dose inhalers (mdi)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/831,888 Expired - Fee Related US7347199B1 (en) 1998-11-25 1999-11-23 Pressurised metered dose inhalers (MDI)
US10/244,519 Expired - Fee Related US7223381B2 (en) 1998-11-25 2002-09-17 Pressurised metered dose inhalers (MDI)

Family Applications After (5)

Application Number Title Priority Date Filing Date
US10/612,072 Expired - Fee Related US7740463B2 (en) 1998-11-25 2003-07-03 Pressurised metered dose inhalers (MDI)
US11/060,564 Abandoned US20050142071A1 (en) 1998-11-25 2005-02-18 Pressurised metered dose inhalers (MDI)
US12/023,315 Expired - Fee Related US8142763B2 (en) 1998-11-25 2008-01-31 Pressurized metered dose inhalers (MDI) containing a solution comprising ipratropium bromide, HFA propellant, and co-solvent and comprising a container with a specific internal surface composition and/or lining
US12/132,852 Abandoned US20080247965A1 (en) 1998-11-25 2008-06-04 Pressurised metered dose inhalers (mdi)
US13/004,204 Abandoned US20110100361A1 (en) 1998-11-25 2011-01-11 Pressurised metered dose inhalers (mdi)

Country Status (36)

Country Link
US (8) US7347199B1 (en)
EP (4) EP1131051B1 (en)
JP (1) JP2002530156A (en)
KR (1) KR100696746B1 (en)
CN (1) CN1200690C (en)
AR (1) AR021391A1 (en)
AT (2) ATE485812T1 (en)
AU (1) AU764696C (en)
BG (1) BG65596B1 (en)
BR (1) BR9916868B1 (en)
CA (2) CA2352484C (en)
CO (1) CO5170487A1 (en)
CY (1) CY1105356T1 (en)
CZ (1) CZ301305B6 (en)
DE (3) DE69929358T2 (en)
DK (1) DK1131051T3 (en)
DZ (1) DZ2947A1 (en)
EA (1) EA004132B1 (en)
EE (1) EE04259B1 (en)
EG (1) EG25278A (en)
ES (1) ES2255767T3 (en)
GE (1) GEP20033129B (en)
HK (1) HK1040063B (en)
HU (1) HU226735B1 (en)
IL (3) IL143294A0 (en)
MA (1) MA26764A1 (en)
NO (1) NO330194B1 (en)
NZ (2) NZ511926A (en)
PL (2) PL200658B1 (en)
SA (1) SA99200825B1 (en)
SI (1) SI1131051T1 (en)
SK (1) SK285246B6 (en)
TN (1) TNSN99220A1 (en)
TR (2) TR200704956T2 (en)
TW (1) TWI226247B (en)
WO (1) WO2000030608A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190289A1 (en) * 2000-05-12 2003-10-09 David Lewis Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
US20030190287A1 (en) * 1997-06-13 2003-10-09 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US20040033201A1 (en) * 1999-06-18 2004-02-19 3M Innovative Properties Company Process for making chemically stable C-17/21 OH 20-ketosteroid aerosol products
US20040126325A1 (en) * 2002-03-12 2004-07-01 David Lewis Medicinal aerosol solution formulation products with improved chemical stability
US20050008578A1 (en) * 2003-07-11 2005-01-13 Boehringer Ingelheim International Gmbh HFC solution formulations containing an anticholinergic
US20050034720A1 (en) * 2000-01-07 2005-02-17 Gaetano Brambilla Aerosol inhaler
US20050101625A1 (en) * 2003-09-26 2005-05-12 Boehringer Ingelheim International Gmbh Aerosol formulation for inhalation comprising an anticholinergic
US20050129621A1 (en) * 2002-03-01 2005-06-16 Chiesi Farmaceutici S.P.A. Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
US20050136009A1 (en) * 2003-10-20 2005-06-23 Schering Corporation Pharmaceutical compositions
US20050142071A1 (en) * 1998-11-25 2005-06-30 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20050152846A1 (en) * 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
US20050163722A1 (en) * 2001-07-02 2005-07-28 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
WO2005084640A1 (en) * 2004-02-27 2005-09-15 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US6967017B1 (en) 1999-07-23 2005-11-22 Chiesi Farmaceutici S.P.A. Formulations of steroid solutions for inhalatory administration
US20060002863A1 (en) * 2004-07-02 2006-01-05 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant
US6983743B2 (en) 1999-05-26 2006-01-10 Boehringer Ingelheim Pharma Kg Stainless steel canister for propellant-driven metering aerosols
US20060083693A1 (en) * 2000-05-22 2006-04-20 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20060099149A1 (en) * 2003-05-21 2006-05-11 Karib Kemi-Pharm Limited Metered dose inhaler product
US20060120966A1 (en) * 2002-10-23 2006-06-08 Chiesi Farmaceutici S.P.A. Salmeterol superfine formulation
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US20070025920A1 (en) * 2004-02-27 2007-02-01 David Lewis Stable Pharmaceutical Solution Formulations for Pressurized Metered Dose Inhalers
EP1915985A1 (en) 2003-03-20 2008-04-30 Boehringer Ingelheim Pharmaceuticals Inc. Formulation for a Metered Dose Inhaler Using Hydro-Fluoro-Alkanes as Propellants
CN100457087C (en) * 2004-02-27 2009-02-04 奇斯药制品公司 Stable pharmaceutical solution formulation for pressurized metered dose inhalers
US20090092559A1 (en) * 2006-04-11 2009-04-09 Boehringer Ingelheim Pharma Gbmh Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
US20090145427A1 (en) * 2007-12-07 2009-06-11 Groeger Joseph H Method for Applying a Polymer Coating to an Internal Surface of a Container
US20090298802A1 (en) * 2005-03-30 2009-12-03 Sequeira Joel A Pharmaceutical Compositions
US7914770B2 (en) 2003-03-20 2011-03-29 Boehringer Ingelheim Pharmaceuticals, Inc. Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (en) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (en) 1998-06-11 1998-06-11 Astra Ab New use
IT1317846B1 (en) * 2000-02-22 2003-07-15 Chiesi Farma Spa FORMULATIONS CONTAINING AN ANTICOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY.
DE10062712A1 (en) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and corticosteroids
US20020085978A1 (en) * 2000-11-10 2002-07-04 Mina Buenafe Degradation-resistant glucocorticosteroid formulations
EP1241113A1 (en) * 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein
GB0106046D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Canister
DE10130371A1 (en) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics, corticosteroids and betamimetics
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
DE10214263A1 (en) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA suspension formulations containing an anticholinergic
WO2004071488A1 (en) * 2003-02-04 2004-08-26 Chrysalis Technologies Incorporated Perfluorocarbon and hydrofluorocarbon formulations and methods of making and using same
WO2005000712A1 (en) 2003-06-24 2005-01-06 Cipla Limited Pharmaceutical dispensing aid
EA013405B1 (en) 2005-02-25 2010-04-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Pharmaceutical aerosol composition for pressurized metered dose inhalers
WO2011115778A2 (en) 2010-03-15 2011-09-22 Virginia Commonwealth University Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
RU2568882C2 (en) * 2010-07-16 2015-11-20 Сипла Лимитед Pharmaceutical compositions
TWI399202B (en) 2011-03-17 2013-06-21 Intech Biopharm Ltd The preparation for formulation composition and manufacturing processes of metered dose inhalers treated respiratory diseases
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
CN102379846B (en) * 2011-10-21 2014-07-02 江苏长风药业有限公司 Fluticasone propionate aerosol preparation with hydrofluoroalkane and polyethylene glycol as auxiliary materials
GB201200525D0 (en) * 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
CN103207032A (en) * 2012-01-13 2013-07-17 热敏碟公司 Low-profile temperature sensor probe
KR101313993B1 (en) * 2012-07-24 2013-10-01 한국화학연구원 Nebulizer
DE102013214601B3 (en) 2013-07-25 2014-05-22 Aptar Radolfzell Gmbh Housing for container unit of inhalation device e.g. metered-dose inhaler, for oral administration of pharmaceutical medium, has membrane reversibly deformed based on pressure in pressure chamber and acting together with pushbutton
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
CA2952934A1 (en) * 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
WO2016040323A1 (en) 2014-09-08 2016-03-17 Becton, Dickinson And Company System and method for preparing a pharmaceutical compound
CN106620976B (en) * 2016-12-28 2020-01-07 四川普锐特医药科技有限责任公司 Fluticasone propionate quantitative inhalation aerosol
US10231948B2 (en) 2017-02-27 2019-03-19 Jason Ty Nguyen Metered dose inhaler compositions, systems, and methods
CN112423820A (en) * 2018-06-13 2021-02-26 帕夫法私人有限公司 Device for delivering respiratory tract medicaments

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868691A (en) * 1956-03-21 1959-01-13 Riker Laboratories Inc Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) * 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
US4835145A (en) * 1984-06-11 1989-05-30 Sicor Societa' Italiana Corticosteroidi S.P.A. 16,17 acetals of pregnane derivatives and pharmaceutical compositions containing them
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US5955058A (en) * 1992-12-09 1999-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations containing ipratropium bromide
US6045784A (en) * 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
US6131565A (en) * 1996-12-20 2000-10-17 Stanwell Corporation Limited Solar energy collector system
US6143277A (en) * 1995-04-14 2000-11-07 Glaxo Wellcome Inc. Metered dose inhaler for salmeterol
US6150418A (en) * 1998-10-17 2000-11-21 Boehringer Ingelheim Pharma Kg Active substance concentrate with formoterol, suitable for storage
US6253762B1 (en) * 1995-04-14 2001-07-03 Glaxo Wellcome Inc. Metered dose inhaler for fluticasone propionate
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
US20030066525A1 (en) * 1998-11-25 2003-04-10 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20030190289A1 (en) * 2000-05-12 2003-10-09 David Lewis Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
US20040047809A1 (en) * 2000-05-22 2004-03-11 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US6713047B1 (en) * 1998-11-25 2004-03-30 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition containing HFA 227 and HFA 134a
US20050129621A1 (en) * 2002-03-01 2005-06-16 Chiesi Farmaceutici S.P.A. Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
US20050154013A1 (en) * 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers containing solutions of beta-2 agonists
US20050220718A1 (en) * 2004-02-27 2005-10-06 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US6964759B2 (en) * 2000-02-22 2005-11-15 Chiesi Farmaceutici S.P.A. Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease
US20060120966A1 (en) * 2002-10-23 2006-06-08 Chiesi Farmaceutici S.P.A. Salmeterol superfine formulation

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US220718A (en) * 1879-10-21 Improvement in street-car warmers
US154013A (en) * 1874-08-11 Improvement in carriage-lamps
US3361306A (en) * 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
CA882187A (en) 1968-03-13 1971-09-28 Farbenfabriken Bayer Aktiengesellschaft Thermoplastic-elastic moulding compounds
US3622053A (en) * 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
MX3864E (en) 1975-05-27 1981-08-26 Syntex Corp A PROCESS TO PREPARE THE CRYSTALLINE COMPOUND 6-FLUIRO-11B 21-DIHIROXI-16 17-ISOPROPILIDENDIOXIPREGNA-1 4-DIEN-3 20-DIONA
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US4584320A (en) * 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Aerosol propellant compositions
ATE116460T1 (en) 1990-02-14 1995-01-15 Systec Ausbausysteme Gmbh TRANSPORT TROLLEY WITH COIN LOCK.
IT1244441B (en) * 1990-09-13 1994-07-15 Chiesi Farma Spa MOUTH INHALATION DEVICE FOR AEROSOL DRUGS
EP0563048A1 (en) * 1990-12-19 1993-10-06 Smithkline Beecham Corporation Aerosol formulations
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
EP0585379B1 (en) 1991-05-21 1998-09-30 Abbott Laboratories Aerosol inhalation device
DE59209686D1 (en) * 1991-08-29 1999-06-02 Broncho Air Medizintechnik Ag MEDICAL DEVICE FOR INHALING DOSING AEROSOLS
NZ244439A (en) 1991-09-25 1994-01-26 Fisons Plc Pressurised aerosol compositions comprising hydrofluoroalkane, dispersed
US5219882A (en) 1991-10-24 1993-06-15 Emil Bisaccia Treatment methods for lymes disease and associated debilitating conditions
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
PT717987E (en) 1991-12-18 2001-12-28 Minnesota Mining & Mfg SUSPENSION FORMULATIONS IN AEROSOL
DE4230876A1 (en) 1992-03-17 1993-09-23 Asta Medica Ag COMPRESSED GAS PACKS USING POLYOXYETHYLENE GLYCERYL OLEATES
SE9203743D0 (en) 1992-12-11 1992-12-11 Astra Ab EFFICIENT USE
WO1994014490A1 (en) 1992-12-23 1994-07-07 Bernhard Hugemann Compacted drug body for use in the mechanical generation of inhalable active-substance particles
JP3987963B2 (en) 1993-03-17 2007-10-10 スリーエム カンパニー Aerosol formulations containing ester-, amide- or mercaptoester-derived dispersion promoters
JPH08507792A (en) 1993-03-17 1996-08-20 ミネソタ マイニング アンド マニュファクチャリング カンパニー Aerosol formulations containing dispersion aids derived from diol-diacids
US5899201A (en) * 1993-05-26 1999-05-04 Minnesota Mining And Manufacturing Company Aerosol actuator
US6596260B1 (en) * 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
WO1995017195A1 (en) * 1993-12-20 1995-06-29 Minnesota Mining And Manufacturing Company Flunisolide aerosol formulations
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
EP0806940B1 (en) 1994-12-22 2003-04-09 AstraZeneca AB Aerosol drug formulations
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DE4446891A1 (en) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stable aqueous budesonide solution
US5653961A (en) 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
HUP9800641A3 (en) * 1995-04-14 2001-04-28 Glaxo Wellcome Inc Res Triangl Metered dose inhaler for beclomethasone dipropionate
CA2217950C (en) * 1995-04-14 2001-12-25 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
US5637505A (en) * 1995-05-19 1997-06-10 Chiron Diagnostics Corporation Method to prepare dye-based reference material
GB9526392D0 (en) * 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
JP2000514085A (en) 1996-07-08 2000-10-24 ローヌ―プーラン・ロウラー・リミテッド Pharmaceutical cyclosporin A aerosol solution formulation
AU3811897A (en) 1996-07-24 1998-02-10 Oglios Therapeutics, Inc. Antisense oligonucleotides as antibacterial agents
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9620187D0 (en) 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
DE69734017T2 (en) 1996-12-04 2006-06-14 Link Products Ltd DRUG COMPOSITIONS AND DEVICES FOR THEIR ADMINISTRATION
DK1014943T3 (en) * 1997-02-05 2002-10-14 Jago Res Ag Medical aerosol formulations
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
PT991734E (en) 1997-06-12 2002-02-28 Pac Holding Sa PROCESS FOR THE ELIMINATION OF RESIDUAL PRODUCTS CONTAINING HYDROCARBONS AND / OR HALOGENATED DERIVATIVES
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
BR7702049U (en) 1997-09-05 1999-09-14 Chiesi Farma Spa Spray nozzle for use in an oral inhaler for aerosol medicines
NZ504021A (en) * 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
SE9802073D0 (en) 1998-06-11 1998-06-11 Astra Ab New use
SK284756B6 (en) 1998-06-18 2005-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical preparation for propellant driven metered dose inhalers, where the propellant is fluorohydrocarbon, containing a combination of two or more active substances
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
AU748867B2 (en) 1998-07-24 2002-06-13 Jagotec Ag Medicinal aerosol formulations
ATE234604T1 (en) 1998-08-04 2003-04-15 Jago Res Ag MEDICAL AEROSOL FORMULATIONS
SK285382B6 (en) 1998-10-17 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Storable active substance concentrate with formoterol, composition containing it and its use
US6086379A (en) * 1998-10-20 2000-07-11 Research Foundation Of State University Of New York System and method for training a swimmer
JP2002529498A (en) 1998-11-13 2002-09-10 ヤゴ・リサーチ・アクチェンゲゼルシャフト Dry powder for inhalation
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
EP1158958B1 (en) 1999-03-05 2007-06-06 CHIESI FARMACEUTICI S.p.A. Improved powdery pharmaceutical compositions for inhalation
JP2003518484A (en) 1999-12-24 2003-06-10 グラクソ グループ リミテッド Pharmaceutical aerosol formulations of salmeterol and fluticasone propionate
ES2222294T3 (en) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. OPTIMIZED FORMULATION OF TOBRAMYCIN FOR ADMINISTRATION IN THE FORM OF AEROSOL.
US6808684B2 (en) 2002-04-05 2004-10-26 International Flavors & Fragrance Inc. Fragrance material

Patent Citations (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868691A (en) * 1956-03-21 1959-01-13 Riker Laboratories Inc Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) * 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
US4835145A (en) * 1984-06-11 1989-05-30 Sicor Societa' Italiana Corticosteroidi S.P.A. 16,17 acetals of pregnane derivatives and pharmaceutical compositions containing them
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5955058A (en) * 1992-12-09 1999-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations containing ipratropium bromide
US6253762B1 (en) * 1995-04-14 2001-07-03 Glaxo Wellcome Inc. Metered dose inhaler for fluticasone propionate
US6143277A (en) * 1995-04-14 2000-11-07 Glaxo Wellcome Inc. Metered dose inhaler for salmeterol
US6131565A (en) * 1996-12-20 2000-10-17 Stanwell Corporation Limited Solar energy collector system
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US20030190287A1 (en) * 1997-06-13 2003-10-09 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20030206870A1 (en) * 1997-06-13 2003-11-06 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US20040062720A1 (en) * 1997-06-13 2004-04-01 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6045784A (en) * 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
US6150418A (en) * 1998-10-17 2000-11-21 Boehringer Ingelheim Pharma Kg Active substance concentrate with formoterol, suitable for storage
US20050142071A1 (en) * 1998-11-25 2005-06-30 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20030066525A1 (en) * 1998-11-25 2003-04-10 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US6713047B1 (en) * 1998-11-25 2004-03-30 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition containing HFA 227 and HFA 134a
US20040096399A1 (en) * 1998-11-25 2004-05-20 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
US6964759B2 (en) * 2000-02-22 2005-11-15 Chiesi Farmaceutici S.P.A. Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease
US20030190289A1 (en) * 2000-05-12 2003-10-09 David Lewis Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
US6716414B2 (en) * 2000-05-22 2004-04-06 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20040047809A1 (en) * 2000-05-22 2004-03-11 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US7018618B2 (en) * 2000-05-22 2006-03-28 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20060083693A1 (en) * 2000-05-22 2006-04-20 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20050129621A1 (en) * 2002-03-01 2005-06-16 Chiesi Farmaceutici S.P.A. Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
US20050154013A1 (en) * 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers containing solutions of beta-2 agonists
US20050152846A1 (en) * 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
US20060120966A1 (en) * 2002-10-23 2006-06-08 Chiesi Farmaceutici S.P.A. Salmeterol superfine formulation
US20050220718A1 (en) * 2004-02-27 2005-10-06 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601336B2 (en) * 1997-06-13 2009-10-13 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20030190287A1 (en) * 1997-06-13 2003-10-09 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US20030206870A1 (en) * 1997-06-13 2003-11-06 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US20090311196A1 (en) * 1997-06-13 2009-12-17 Chiesi Farmaceutici S.P.A Pharmaceutical aerosol composition
US20040062720A1 (en) * 1997-06-13 2004-04-01 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US8420058B2 (en) 1997-06-13 2013-04-16 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US8142763B2 (en) 1998-11-25 2012-03-27 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhalers (MDI) containing a solution comprising ipratropium bromide, HFA propellant, and co-solvent and comprising a container with a specific internal surface composition and/or lining
US20080115782A1 (en) * 1998-11-25 2008-05-22 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (mdi)
US20080247965A1 (en) * 1998-11-25 2008-10-09 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (mdi)
US20050142071A1 (en) * 1998-11-25 2005-06-30 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US6983743B2 (en) 1999-05-26 2006-01-10 Boehringer Ingelheim Pharma Kg Stainless steel canister for propellant-driven metering aerosols
US20050220717A1 (en) * 1999-06-18 2005-10-06 3M Innovative Properties Company Steroid solution aerosol products with enhanced chemical stability
US20040033201A1 (en) * 1999-06-18 2004-02-19 3M Innovative Properties Company Process for making chemically stable C-17/21 OH 20-ketosteroid aerosol products
US6967017B1 (en) 1999-07-23 2005-11-22 Chiesi Farmaceutici S.P.A. Formulations of steroid solutions for inhalatory administration
US20050034720A1 (en) * 2000-01-07 2005-02-17 Gaetano Brambilla Aerosol inhaler
US20030190289A1 (en) * 2000-05-12 2003-10-09 David Lewis Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
US20060083693A1 (en) * 2000-05-22 2006-04-20 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US8168598B2 (en) 2001-07-02 2012-05-01 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US7696178B2 (en) 2001-07-02 2010-04-13 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US20050163722A1 (en) * 2001-07-02 2005-07-28 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US20100098642A1 (en) * 2001-07-02 2010-04-22 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US7939502B2 (en) 2001-07-02 2011-05-10 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US20110212912A1 (en) * 2001-07-02 2011-09-01 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US20050154013A1 (en) * 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers containing solutions of beta-2 agonists
US20090263488A1 (en) * 2002-03-01 2009-10-22 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers containing solutions of beta-2 agonists
US8313732B2 (en) 2002-03-01 2012-11-20 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
US20050129621A1 (en) * 2002-03-01 2005-06-16 Chiesi Farmaceutici S.P.A. Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
US20110061651A1 (en) * 2002-03-01 2011-03-17 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
US20050152846A1 (en) * 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
US20040126325A1 (en) * 2002-03-12 2004-07-01 David Lewis Medicinal aerosol solution formulation products with improved chemical stability
US20060120966A1 (en) * 2002-10-23 2006-06-08 Chiesi Farmaceutici S.P.A. Salmeterol superfine formulation
US8088362B2 (en) 2002-10-23 2012-01-03 Chiesi Farmaceutici S.P.A. Salmeterol superfine formulation
EP1915985A1 (en) 2003-03-20 2008-04-30 Boehringer Ingelheim Pharmaceuticals Inc. Formulation for a Metered Dose Inhaler Using Hydro-Fluoro-Alkanes as Propellants
US7914770B2 (en) 2003-03-20 2011-03-29 Boehringer Ingelheim Pharmaceuticals, Inc. Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants
US20060099149A1 (en) * 2003-05-21 2006-05-11 Karib Kemi-Pharm Limited Metered dose inhaler product
US7273603B2 (en) * 2003-07-11 2007-09-25 Boehringer Ingelheim International Gmbh HFC solution formulations containing an anticholinergic
US20050008578A1 (en) * 2003-07-11 2005-01-13 Boehringer Ingelheim International Gmbh HFC solution formulations containing an anticholinergic
US20050101625A1 (en) * 2003-09-26 2005-05-12 Boehringer Ingelheim International Gmbh Aerosol formulation for inhalation comprising an anticholinergic
US7579358B2 (en) * 2003-09-26 2009-08-25 Boehringer Ingelheim International Gmbh Aerosol formulation for inhalation comprising an anticholinergic
US20050136009A1 (en) * 2003-10-20 2005-06-23 Schering Corporation Pharmaceutical compositions
US20080064674A1 (en) * 2003-10-20 2008-03-13 Schering Corporation Pharmaceutical Compositions
WO2005084640A1 (en) * 2004-02-27 2005-09-15 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20070025920A1 (en) * 2004-02-27 2007-02-01 David Lewis Stable Pharmaceutical Solution Formulations for Pressurized Metered Dose Inhalers
CN100457087C (en) * 2004-02-27 2009-02-04 奇斯药制品公司 Stable pharmaceutical solution formulation for pressurized metered dose inhalers
EA010311B1 (en) * 2004-02-27 2008-08-29 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Aerosol solution formulations, pressurized metered dose inhalers and method for filling thereof
US7381402B2 (en) 2004-02-27 2008-06-03 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US8357352B2 (en) 2004-07-02 2013-01-22 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant
US20060002863A1 (en) * 2004-07-02 2006-01-05 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant
US20090298802A1 (en) * 2005-03-30 2009-12-03 Sequeira Joel A Pharmaceutical Compositions
US20090092559A1 (en) * 2006-04-11 2009-04-09 Boehringer Ingelheim Pharma Gbmh Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
US8518377B2 (en) 2006-04-11 2013-08-27 Boehringer Ingelheim Pharma Gbmh Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
US8227027B2 (en) 2007-12-07 2012-07-24 Presspart Gmbh & Co. Kg Method for applying a polymer coating to an internal surface of a container
US20090145427A1 (en) * 2007-12-07 2009-06-11 Groeger Joseph H Method for Applying a Polymer Coating to an Internal Surface of a Container
US8703306B2 (en) 2007-12-07 2014-04-22 Presspart Gmbh & Co. Kg Method for applying a polymer coating to an internal surface of a container

Also Published As

Publication number Publication date
US8142763B2 (en) 2012-03-27
DE69942896D1 (en) 2010-12-09
PL200658B1 (en) 2009-01-30
EA200100468A1 (en) 2001-12-24
US7740463B2 (en) 2010-06-22
JP2002530156A (en) 2002-09-17
TWI226247B (en) 2005-01-11
ES2255767T3 (en) 2006-07-01
EE04259B1 (en) 2004-04-15
KR20010080543A (en) 2001-08-22
IL143294A0 (en) 2002-04-21
HK1040063B (en) 2006-04-21
TR200704956T2 (en) 2008-01-21
SA99200825B1 (en) 2006-11-07
CA2352484A1 (en) 2000-06-02
HK1040063A1 (en) 2002-05-24
NO20012516L (en) 2001-07-23
NZ511926A (en) 2003-10-31
SI1131051T1 (en) 2006-04-30
CN1200690C (en) 2005-05-11
CN1328445A (en) 2001-12-26
CZ20011834A3 (en) 2001-12-12
MA26764A1 (en) 2004-12-20
EG25278A (en) 2011-12-05
SK285246B6 (en) 2006-09-07
US20110100361A1 (en) 2011-05-05
US20050142071A1 (en) 2005-06-30
ATE485812T1 (en) 2010-11-15
DE69929358T2 (en) 2006-07-13
BR9916868A (en) 2001-11-06
US20030066525A1 (en) 2003-04-10
EP1674079A3 (en) 2006-07-05
TNSN99220A1 (en) 2001-12-31
AU764696C (en) 2004-06-24
US7347199B1 (en) 2008-03-25
CY1105356T1 (en) 2010-03-03
EP1131051A1 (en) 2001-09-12
HU226735B1 (en) 2009-08-28
NO20012516D0 (en) 2001-05-22
AU1556300A (en) 2000-06-13
EP1523975A2 (en) 2005-04-20
US20080247965A1 (en) 2008-10-09
KR100696746B1 (en) 2007-03-19
DK1131051T3 (en) 2006-04-18
EP1523975A3 (en) 2005-08-31
PL348717A1 (en) 2002-06-03
DE69929358D1 (en) 2006-03-30
CA2352484C (en) 2010-05-04
TR200101441T2 (en) 2001-08-21
CA2698376A1 (en) 2000-06-02
BG105532A (en) 2001-12-29
WO2000030608A1 (en) 2000-06-02
CZ301305B6 (en) 2010-01-06
EP1674079A2 (en) 2006-06-28
AR021391A1 (en) 2002-07-17
NZ527190A (en) 2005-04-29
DE29923839U1 (en) 2001-03-01
EP1666029A1 (en) 2006-06-07
IL143294A (en) 2007-05-15
HUP0104411A3 (en) 2002-12-28
AU764696B2 (en) 2003-08-28
IL179491A0 (en) 2007-05-15
EP1131051B1 (en) 2006-01-04
CO5170487A1 (en) 2002-06-27
US20080115782A1 (en) 2008-05-22
HUP0104411A2 (en) 2002-03-28
US20040096399A1 (en) 2004-05-20
US7223381B2 (en) 2007-05-29
EE200100276A (en) 2002-12-16
BG65596B1 (en) 2009-02-27
SK7042001A3 (en) 2001-11-06
ATE314838T1 (en) 2006-02-15
BR9916868B1 (en) 2011-02-08
EA004132B1 (en) 2003-12-25
PL204572B1 (en) 2010-01-29
DZ2947A1 (en) 2004-03-15
EP1523975B1 (en) 2010-10-27
NO330194B1 (en) 2011-03-07
GEP20033129B (en) 2003-12-25

Similar Documents

Publication Publication Date Title
US7347199B1 (en) Pressurised metered dose inhalers (MDI)
EP0588897B1 (en) Non-chlorofluorocarbon aerosol formulations
EP0587790B2 (en) Non-chlorofluorocarbon aerosol formulations
JP5392880B2 (en) Stable pharmaceutical solution formulation for pressurized metered dose inhalers
EP1368253B1 (en) Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein
ZA200104222B (en) Pressurised metered dose inhalers (MDI).
ITMI991712A1 (en) PRESSURIZED DOSED INHALERS

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION